Scotiabank lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $65 from $71 and keeps an Outperform rating on the shares. The firm expects mitapivat’s upcoming Prescription Drug User Fee Act, PDUFA, on September 7th and the launch in thalassemia will be a key focus in the upcoming earnings call, the analyst tells investors. Additionally, the company may provide details on what constitutes a successful readout related to its RISE UP study for sickle cell disease, which could unlock the next phase of upside, the firm adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- Agios Pharmaceuticals price target lowered to $51 from $52 at BofA
- Agios Pharma Appoints Dr. Jay Backstrom as Director
- Agios Pharmaceuticals appoints Jay Backstrom to board
- Agios Pharma Increases Shares in Stock Incentive Plan
- Agios Pharma’s Strategic Partnerships and Promising Drug Developments Drive Buy Rating